» Articles » PMID: 34322545

Challenging the Obesity Paradox: Extreme Obesity and COPD Mortality in the SUMMIT Trial

Abstract

Populations with COPD demonstrate higher survival in overweight and obese compared with normal weight; the "obesity paradox". Relationships in less-severe COPD are unclear, as is the impact of cardiovascular risk, and few studies include individuals at extremes of obesity.  We examined the relationship between body mass index (BMI; defined as underweight: <20 kg·m, normal: 20-25 kg·m, overweight: 25- <30 kg·m, obese class I: 30- <35 kg·m, class II: 35- <40 kg·m and class III: ≥40 kg·m), morbidity, and mortality in the SUMMIT trial population (n=16 485), characterised by moderate COPD and heightened cardiovascular risk with a substantial proportion with class III obesity. The association between BMI category and time to event was modelled proportional hazards (reference normal weight) adjusted for demographics and cardiorespiratory disease.  Consistent with the paradox, underweight individuals demonstrated higher mortality (hazard ratio (HR) 1.31 (95% CI 1.04-1.64)), with lower mortality among overweight (HR 0.62 (95% CI 0.52-0.73)) and obese class I (HR 0.75 (95% CI 0.62-0.90)). However, mortality increased in obese class III (HR 1.36 (95% CI 1.00-1.86)). Death was primarily attributable to cardiovascular causes.  Within a large, multinational cohort with moderate COPD and increased cardiovascular risk, the phenomenon of reduced mortality with obesity did not persist at BMI >40 kg·m, suggesting that obesity may not remain protective at the extremes in this population.

Citing Articles

Therapeutic Management in Patients with Chronic Obstructive Pulmonary Disease Who Are Overweight or Obese: A Systematic Review and Meta-Analysis.

Chami-Pena S, Caballero-Vazquez A, Mebrive-Jimenez M, Gomez-Urquiza J, Romero-Bejar J, Caballero-Mateos A J Clin Med. 2025; 14(4).

PMID: 40004760 PMC: 11856468. DOI: 10.3390/jcm14041230.


Adolescent Obesity and Charlson Comorbidity Index in Young Adults.

Treister-Goltzman Y, Menashe I, Nemet D J Clin Med. 2025; 14(3).

PMID: 39941543 PMC: 11818213. DOI: 10.3390/jcm14030873.


Metabolic Health, Overweight or Obesity, and Lung Function in Older Australian Adults.

Opio J, Wynne K, Attia J, Hancock S, McEvoy M Nutrients. 2025; 16(24.

PMID: 39770878 PMC: 11676256. DOI: 10.3390/nu16244256.


The impact of body mass index on mortality in COPD: an updated dose-response meta-analysis.

Tenda E, Henrina J, Setiadharma A, Felix I, Yulianti M, Pitoyo C Eur Respir Rev. 2024; 33(174).

PMID: 39603663 PMC: 11600125. DOI: 10.1183/16000617.0261-2023.


Malnutrition and Obesity in Patients with COPD Exacerbation, Insights from the National Inpatient Sample.

El Labban M, El-Zibaoui R, Usama S, Niaz F, Cohen A, Krastev P Open Respir Med J. 2024; 18:e18743064322829.

PMID: 39450126 PMC: 11499682. DOI: 10.2174/0118743064322829240801094830.


References
1.
. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403):157-63. DOI: 10.1016/S0140-6736(03)15268-3. View

2.
Flegal K, Kit B, Orpana H, Graubard B . Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013; 309(1):71-82. PMC: 4855514. DOI: 10.1001/jama.2012.113905. View

3.
Morse S, Gulati R, Reisin E . The obesity paradox and cardiovascular disease. Curr Hypertens Rep. 2010; 12(2):120-6. DOI: 10.1007/s11906-010-0099-1. View

4.
Schols A, Ferreira I, Franssen F, Gosker H, Janssens W, Muscaritoli M . Nutritional assessment and therapy in COPD: a European Respiratory Society statement. Eur Respir J. 2014; 44(6):1504-20. DOI: 10.1183/09031936.00070914. View

5.
Banack H, Kaufman J . The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev Med. 2014; 62:96-102. DOI: 10.1016/j.ypmed.2014.02.003. View